SYS-CON MEDIA Authors: Dana Gardner, Peter Silva, Kevin Jackson, Jessica Qiu, Dan Stolts

News Feed Item

Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256137/Metachromatic-Leukodystrophy-MLD-Global-Clinical-Trials-Review-H2-2014.html

Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014" provides data on the Metachromatic Leukodystrophy (MLD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metachromatic Leukodystrophy (MLD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metachromatic Leukodystrophy (MLD). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Metachromatic Leukodystrophy (MLD) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Metachromatic Leukodystrophy (MLD) 24
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27

Prominent Sponsors 28
Top Companies Participating in Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Shire Plc 31
Clinical Trial Overview of Shire Plc 31
The Cooper Companies, Inc. 32
Clinical Trial Overview of The Cooper Companies, Inc. 32
GlaxoSmithKline plc 33
Clinical Trial Overview of GlaxoSmithKline plc 33
Cytomedix, Inc. 34
Clinical Trial Overview of Cytomedix, Inc. 34
Clinical Trial Overview of Top Institutes / Government 35
University of Louisville 35
Clinical Trial Overview of University of Louisville 35
IRCCS San Raffaele Milano 36
Clinical Trial Overview of IRCCS San Raffaele Milano 36

Fondazione San Raffaele del Monte Tabor 37
Clinical Trial Overview of Fondazione San Raffaele del Monte Tabor 37
University of Rostock 38
Clinical Trial Overview of University of Rostock 38
Fairview University Medical Center 39
Clinical Trial Overview of Fairview University Medical Center 39
New York Medical College 40
Clinical Trial Overview of New York Medical College 40
Masonic Cancer Center 41
Clinical Trial Overview of Masonic Cancer Center 41
Institut National de la Sante et de la Recherche Medicale 42
Clinical Trial Overview of Institut National de la Sante et de la Recherche Medicale 42
National Center for Research Resources 43
Clinical Trial Overview of National Center for Research Resources 43
Assistance Publique - Hopitaux de Paris 44
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 44
Five Key Clinical Profiles 45
Appendix 68
Abbreviations 68
Definitions 68
Research Methodology 69
Secondary Research 69
About GlobalData 70
Contact Us 70
Disclaimer 70
Source 70

List of Tables

Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16

Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Metachromatic Leukodystrophy (MLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23

Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Suspended Clinical Trials, 2014* 24
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Metachromatic Leukodystrophy (MLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Shire Plc, 2014* 31
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by The Cooper Companies, Inc., 2014* 32
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 33
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytomedix, Inc., 2014* 34
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Louisville, 2014* 35
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by IRCCS San Raffaele Milano, 2014* 36

Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fondazione San Raffaele del Monte Tabor, 2014* 37
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Rostock, 2014* 38
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fairview University Medical Center, 2014* 39
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by New York Medical College, 2014* 40
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2014* 41
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Institut National de la Sante et de la Recherche Medicale, 2014* 42
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Center for Research Resources, 2014* 43
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 44

List of Figures

Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15

Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Metachromatic Leukodystrophy (MLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Metachromatic Leukodystrophy (MLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 69

To order this report: Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256137/Metachromatic-Leukodystrophy-MLD-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water, are pursuing SmartGrid initiatives that represent one of the more mature examples of SAE. We have s...
The Internet of Things (IoT) is going to require a new way of thinking and of developing software for speed, security and innovation. This requires IT leaders to balance business as usual while anticipating for the next market and technology trends. Cloud provides the right IT asset portfolio to help today’s IT leaders manage the old and prepare for the new. Today the cloud conversation is evolving from private and public to hybrid. This session will provide use cases and insights to reinforce the value of the network in helping organizations to maximize their company’s cloud experience.
IoT is still a vague buzzword for many people. In his session at Internet of @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, will discuss the business value of IoT that goes far beyond the general public's perception that IoT is all about wearables and home consumer services. The presentation will also discuss how IoT is perceived by investors and how venture capitalist access this space. Other topics to discuss are barriers to success, what is new, what is old, and what the future may hold.
Whether you're a startup or a 100 year old enterprise, the Internet of Things offers a variety of new capabilities for your business. IoT style solutions can help you get closer your customers, launch new product lines and take over an industry. Some companies are dipping their toes in, but many have already taken the plunge, all while dramatic new capabilities continue to emerge. In his session at Internet of @ThingsExpo, Reid Carlberg, Senior Director, Developer Evangelism at salesforce.com, to discuss real-world use cases, patterns and opportunities you can harness today.
All major researchers estimate there will be tens of billions devices – computers, smartphones, tablets, and sensors – connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be!
Noted IoT expert and researcher Joseph di Paolantonio (pictured below) has joined the @ThingsExpo faculty. Joseph, who describes himself as an “Independent Thinker” from DataArchon, will speak on the topic of “Smart Grids & Managing Big Utilities.” Over his career, Joseph di Paolantonio has worked in the energy, renewables, aerospace, telecommunications, and information technology industries. His expertise is in data analysis, system engineering, Bayesian statistics, data warehouses, business intelligence, data mining, predictive methods, and very large databases (VLDB). Prior to DataArcho...
Software AG helps organizations transform into Digital Enterprises, so they can differentiate from competitors and better engage customers, partners and employees. Using the Software AG Suite, companies can close the gap between business and IT to create digital systems of differentiation that drive front-line agility. We offer four on-ramps to the Digital Enterprise: alignment through collaborative process analysis; transformation through portfolio management; agility through process automation and integration; and visibility through intelligent business operations and big data.
There will be 50 billion Internet connected devices by 2020. Today, every manufacturer has a propriety protocol and an app. How do we securely integrate these "things" into our lives and businesses in a way that we can easily control and manage? Even better, how do we integrate these "things" so that they control and manage each other so our lives become more convenient or our businesses become more profitable and/or safe? We have heard that the best interface is no interface. In his session at Internet of @ThingsExpo, Chris Matthieu, Co-Founder & CTO at Octoblu, Inc., will discuss how thes...
Last week, while in San Francisco, I used the Uber app and service four times. All four experiences were great, although one of the drivers stopped for 30 seconds and then left as I was walking up to the car. He must have realized I was a blogger. None the less, the next car was just a minute away and I suffered no pain. In this article, my colleague, Ved Sen, Global Head, Advisory Services Social, Mobile and Sensors at Cognizant shares his experiences and insights.
We are reaching the end of the beginning with WebRTC and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a variety of different PaaS/SaaS offerings – and you want to add real-time communications you are faced with a challenge relating to user management, authentication, authorization, and validation. Service providers will want to use their existing identities, but these will have credentials already that are (hopefully) ir...
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. It also ensured scalability and better service for customers, including MUY! Companies, one of the country's largest franchise restaurant companies with 232 Pizza Hut locations. This is one example of WebRTC adoption today, but the potential is limitless when powered by IoT. Attendees will learn rea...
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at Internet of @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, will share some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, deploy, and manage applications integrating voice, video and data. He is the co-founder ...
The Internet of Things (IoT) promises to create new business models as significant as those that were inspired by the Internet and the smartphone 20 and 10 years ago. What business, social and practical implications will this phenomenon bring? That's the subject of "Monetizing the Internet of Things: Perspectives from the Front Lines," an e-book released today and available free of charge from Aria Systems, the leading innovator in recurring revenue management.
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges.
There’s Big Data, then there’s really Big Data from the Internet of Things. IoT is evolving to include many data possibilities like new types of event, log and network data. The volumes are enormous, generating tens of billions of logs per day, which raise data challenges. Early IoT deployments are relying heavily on both the cloud and managed service providers to navigate these challenges. In her session at 6th Big Data Expo®, Hannah Smalltree, Director at Treasure Data, to discuss how IoT, Big Data and deployments are processing massive data volumes from wearables, utilities and other mach...
P2P RTC will impact the landscape of communications, shifting from traditional telephony style communications models to OTT (Over-The-Top) cloud assisted & PaaS (Platform as a Service) communication services. The P2P shift will impact many areas of our lives, from mobile communication, human interactive web services, RTC and telephony infrastructure, user federation, security and privacy implications, business costs, and scalability. In his session at Internet of @ThingsExpo, Erik Lagerway, Co-founder of Hookflash, will walk through the shifting landscape of traditional telephone and voice s...
While great strides have been made relative to the video aspects of remote collaboration, audio technology has basically stagnated. Typically all audio is mixed to a single monaural stream and emanates from a single point, such as a speakerphone or a speaker associated with a video monitor. This leads to confusion and lack of understanding among participants especially regarding who is actually speaking. Spatial teleconferencing introduces the concept of acoustic spatial separation between conference participants in three dimensional space. This has been shown to significantly improve comprehe...
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, will discuss single-value, geo-spatial, and log time series data. By focusing on enterprise applications and the data center, he will use OpenTSDB as an example...
SYS-CON Events announced today that Gridstore™, the leader in software-defined storage (SDS) purpose-built for Windows Servers and Hyper-V, will exhibit at SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Gridstore™ is the leader in software-defined storage purpose built for virtualization that is designed to accelerate applications in virtualized environments. Using its patented Server-Side Virtual Controller™ Technology (SVCT) to eliminate the I/O blender effect and accelerate applications Gridsto...
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace. These technological reforms have not only changed computers and smartphones, but are also changi...